BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that ended Nov. 12, 2010:
The week's best-performing stocks in the sector:
(APPY - Get Report) (+32%),
(VRML) (+26%) and
Is it any coincidence that Aastrom filed a $75 million mixed shelf registration Friday?
The week's worst-performing stocks: Surmodics (SRDX - Get Report) (-30%), Epicept (EPCT) (-28%), Metabolix (MBLX) (-25%), Angiotech Pharmaceuticals (ANPI) (-21%) and Repros Therapeutics (RPRXD) (-19%).Cadence Pharmaceuticals (CADX) sold 11.5 million shares at $8, raising $86 million to fund commercial launch of Ofirmev, a hospital-based intravenous form of acetameniphan. > > Bull or Bear? Vote in Our Poll Athersys (ATHX - Get Report) received FDA clearance to start phase II study of Multistem stem cell therapy for inflammatory bowel disease. Arena Pharma (ARNA): 'Marginal' Obesity Drug Now Unsafe? Research abstracts for American Society of Hematology annual meeting were posted online. Cerus (CERS) priced 7.37 million stock units (stock and warrants) at $2.85 a unit, raising $20 million. FDA cleared Polymedix (PYMX.OB) to begin human clinical trials of antibiotic PMX-30063. Osiris Therapeutics (OSIR) Drags Feet on U.S. Approval Filing Dendreon (DNDN) filed for FDA approval of an expansion to its Provenge manufacturing plant in New Jersey, while the Centers for Medicare and Medicaid (CMS) released the technical assessment of Dendreon's Provenge ahead of next week's National Coverage Determination meeting. Micromet (MITI) sold 9.9 million shares at $7.30, raising $72 million. This week's Biotech Stock Mailbag: Theratechnologies (TH.TO), Arena Pharmaceuticals, Amarin (AMRN), and Osiris Therapeutics. A preview of next week's important regulatory meetings facing Human Genome Sciences, Dendreon and MELA Sciences (MELA). Human Genome: Benlysta FDA Panel Preview Glaxo (GSK) Lawyer Indicted for Obstructing the FDA (via Pharmalot) European Drug Approval Agency Looking for new leader (via invivo blog) --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.